PremiumPress ReleasesWerewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting